---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-000814"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:23:20.420341+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Technologies maintains CAP accreditation for lab subsidiary PPLS

## Summary
- Precision Pathology Laboratory Services (PPLS) passed rigorous CAP on-site inspection, retaining gold-standard accreditation.
- Reaffirms quality, accuracy, and patient safety for CyPath Lung test and all lab services lines.
- CEO states ongoing CAP accreditation supports value proposition with physicians, health systems, and partners.
- Lung cancer diagnostics market projected to grow from $4.8B (2024) to $10.4B by 2034 at 8.1% CAGR.
- CyPath Lung test demonstrates 92% sensitivity, 87% specificity, 88% accuracy in detecting early-stage lung cancer.

## SEC filing metadata
- accession: 0001493152-26-000814
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226000814/0001493152-26-000814-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226000814/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-000814
- JSON: https://secwatch.observer/filing/0001493152-26-000814.json
- Plain text: https://secwatch.observer/filing/0001493152-26-000814.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.